Under the FDA's Non-Device CDS criteria, which of the following must be true for clinical decision support software to avoid device regulation?
Select one answer.
The problem: polished demos, unproven performance
Most healthcare organizations are choosing AI analytics tools without a structured way to test whether the tool actually does what the vendor claims. Vendor performance statistics are typically derived from internal validation studies using the vendor's own training data, and they rarely disclose how the model performs across different EHR systems or patient populations. That gap is where budgets get wasted and clinician trust erodes.
A workable evaluation starts with the right questions — not the feature list.
Step 1: Interrogate the training data
Before anything else, ask what data the model was trained on. Training data composition determines performance characteristics. A diagnostic model trained predominantly on data from academic medical centers may not generalize to a community hospital's patient mix. Ask for:
- The source systems and geography of the training data
- Whether performance is disclosed across multiple EHRs, not just the vendor's own
- How the vendor handles distribution shift when your population differs from the training set
If the vendor cannot answer these, treat the performance claims as unverified.
Step 2: Determine whether the tool is regulated
Not every AI analytics tool is a medical device. Under Section 520(o)(1)(E) of the Federal Food, Drug, and Cosmetic Act, clinical decision support software can qualify as "Non-Device CDS" — and avoid FDA premarket review — only if it meets four criteria: it does not analyze medical images or signals; it displays, analyzes, or prints medical information; it provides recommendations to a healthcare professional rather than directing them; and it enables the professional to independently review the basis for each recommendation.
That fourth criterion is the one to test hardest. The FDA's evaluation of AI-enabled CDS remains focused on whether the healthcare professional can understand the basis of the recommendation, regardless of whether AI or machine learning produced it. In January 2026, the FDA issued a revised CDS guidance that broadened some interpretations but maintained many existing policies. Ask the vendor directly: which criterion does your product rely on, and can a clinician see why the tool made its recommendation?
Step 3: Test against real-world data, not benchmarks
Benchmark wins do not translate to clinical performance. Clinical AI responses must be evaluated for intent, knowledge integrity, and potential risks, and rigorous real-world testing is essential. The Duke-Margolis Center has recommended that AI-enabled clinical decision and diagnostic support tools be evaluated using real-world data across three areas: performance measures, data access and privacy, and data sharing and security.
Practical steps:
- Run a silent pilot on your own historical data before any clinician sees output
- Compare the tool's recommendations against your existing clinical pathways
- Track false positives and false negatives separately — they carry different clinical costs
- Re-evaluate after deployment, not just before, because workflows and populations change
Step 4: Check workflow fit and integration
AI and data analytics can support earlier risk identification, reduced administrative burden, and better capacity planning — but those outcomes depend on reliable data, healthcare-specific engineering, and workflow integration. A tool that requires clinicians to leave the EHR to see an insight will not get used.
Ask:
- Where does the output appear in the clinician's existing workflow?
- What is the alert burden, and who owns tuning it?
- How does the tool handle missing or conflicting data from your source systems?
Step 5: Build a scoring checklist
Use a simple weighted scorecard so procurement decisions are defensible:
- Training data transparency (weight high)
- Regulatory status clarity — device or non-device CDS (weight high)
- Real-world validation on your data (weight high)
- EHR and workflow integration (weight medium)
- Post-deployment monitoring plan (weight medium)
- Total cost including integration and change management (weight medium)
Score each vendor on evidence, not on the quality of the demo.
The bottom line
Evaluating AI analytics tools for clinical workflows is a data-governance exercise as much as a technology purchase. The organizations that get it right ask about training data, regulatory classification, and real-world performance before they ask about features.
How the Featured Expert Can Help
ArcadientIQ LLC offers healthcare data analytics consulting specializing in Tableau, Alteryx, SQL, and business intelligence solutions. They provide project-based consulting to help organizations improve reporting, automate workflows, and gain operational visibility without building an internal analytics team. Learn more at arcadientiq.com.